Table 3.
Efficacy outcomes with lenalidomide in patients with MCL after ibrutinib failure or intolerance
| Outcome | L (n = 13) | L + R (n = 11) | L + othera (n = 34) | Overall (N = 58) | ||||
|---|---|---|---|---|---|---|---|---|
| No. | % | No. | % | No. | % | No. | % | |
| Best response by investigator’s assessment | ||||||||
| ORR | 2 | 15 | 3 | 27 | 12 | 35 | 17 | 29 |
| 95% CI | 2–45% | 6–61% | 20–54% | 18–43% | ||||
| CR | 0 | 0 | 1 | 9 | 7 | 21 | 8 | 14 |
| PR | 2 | 15 | 2 | 18 | 5 | 15 | 9 | 15 |
| SD | 0 | 0 | 1 | 9 | 3 | 9 | 4 | 7 |
| Relapse/PD | 8 | 62 | 3 | 27 | 16 | 47 | 27 | 47 |
| Unknown | 3 | 23 | 2 | 18 | 3 | 9 | 8 | 14 |
| Missing | 0 | 0 | 2 | 18 | 0 | 0 | 2 | 3 |
| Duration of response, weeks | ||||||||
| KM median | 3 | 20 | NA | 20 | ||||
| 95% CI | NA to NA | NA to NA | 16.4 to NA | 2.9 to NA | ||||
CI confidence interval, CR complete response, KM Kaplan-Meier, L lenalidomide, L + R lenalidomide plus rituximab, MCL mantle cell lymphoma, NA not applicable, PD progressive disease, PR partial response, SD stable disease
aAdditional file 1: Table S2 lists the other treatments